This prospective, randomized controlled trial evaluates whether real-time continuous glucose monitoring (CGM) improves glycemic control and lifestyle adherence in adults with prediabetes compared to conventional self-monitoring methods over a 3-month period. By analyzing metabolic markers and behavioral data, the study aims to determine the effectiveness of 24-hour monitoring as a personalized tool that increases patient adherence to lifestyle changes compared to conventional SMBG methods.
Prediabetes is considered a critical stage at which effective prevention of the development of diabetes is possible, provided that early detection and adequate glycemic control. International clinical guidelines and multicenter studies suggest that early intensive glycemic control is associated with a better prognosis and a reduced risk of complications. However, standard self-monitoring has limited information on glycemic variability, which is especially important in the early stages of carbohydrate metabolism disorders, including prediabetes. Routine indicators such as fasting blood glucose, 1 and 2 hours after a meal, and glycated hemoglobin (HbA1c) do not always clearly differentiate between diabetes, prediabetes, and normal carbohydrate metabolism. Recently, there has been a need for more comprehensive blood glucose monitoring strategies that cover the entire spectrum of glycemic variability. Continuous glucose monitoring (CGMs) technology provides real-time glucose concentration data, overcoming the limitations of traditional monitoring methods. Recently, not only among people with diabetes, but also among people with prediabetes, there has been an increasing trend towards using CGM as a personal device to monitor glucose levels and promote healthy habits such as increased activity, diet, and sleep. Their motivation is to improve their own glycemic control and avoid the future development of diabetes and its associated complications, to optimize blood glucose levels to achieve peak mental or physical performance, and to use personal monitoring data to develop sustainable behavioral skills. The contactless 24-hour monitoring system is considered a promising tool for personalized glycemic control, but its use in people with prediabetes has not been studied enough This is a prospective, open-label, randomized controlled trial involving 80 adult patients with prediabetes recruited at the Bogomolets National Medical University. Participants were randomized in a 1:1 ratio to either the Real-Time Continuous Glucose Monitoring (CGM group) or the control group (standard Self-Monitoring of Blood Glucose \[SMBG\] using conventional glucometers). Participants will undergo a 3-month observation period. The use of the assigned monitoring devices (CGM or SMBG glucometer) and pedometers will last for the first 1 month. The study consists of three visits: Visit 1 (baseline), Visit 2 (1 month, end of intervention), and Visit 3 (3 months, follow-up period). During these visits, researchers will collect data on glycated hemoglobin (HbA1c), fructosamine, Cpeptide, HOMA-IR index, lipid profile, anthropometric indicators (body mass index (BMI), waist circumference), bioimpedance measurement, physical activity monitoring using pedometers, and SF-36 questionnaire to assess quality of life. The gathered data will help determine whether continuous monitoring provided by CGM systems improves glycemic control and increases patient adherence to lifestyle changes compared to conventional SMBG methods.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
80
A registered medical device for real-time monitoring of glucose levels in interstitial fluid.
Capillary glucose monitoring using fingerstick glucometer as per standard care.
Bogomolets National Medical University
Kyiv, Ukraine
RECRUITINGUniversity Hospital of Bogomolets National Medical University
Kyiv, Ukraine
RECRUITINGChanges in HbA1c level
HbA1c in %
Time frame: at 3 month (end of follow-up period)
Changes in Fructosamine level
Fructosamine in μmol/L
Time frame: at 3 month (end of intervention period)
HOMA-2IR
This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php
Time frame: at 3 month (follow-up period) compared to baseline
insulin sensitivity (%S)
This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php
Time frame: at 3 month (follow-up period) compared to baseline
β-cell function (%B)
This model can be calculated using the software supplied by the Oxford Centre for Diabetes Endocrinology and Metabolism available at http://www.dtu.ox.ac.uk/homacalculator/index.php
Time frame: at 3 month (follow-up period) compared to baseline
body mass index (BMI)
weight in kg and height in meters will be combined to report BMI in kg/m\^2
Time frame: at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
waist circumferences (WC)
WC in cm
Time frame: at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
visceral fat content
visceral fat content using electronic scales-analyzers of body composition Huawei (Smart Scale series 3/3 Pro
Time frame: at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
Total Cholesterol (TC)
TC in mmol/l
Time frame: at 3 month (follow-up period) compared to baseline
Tryglicerides (TG)
TG in mmol/l
Time frame: at 3 month (follow-up period) compared to baseline
LDL-Cholesterol (LDL-C)
LDL-C in mmol/l
Time frame: at 3 month (follow-up period) compared to baseline]
Physical activity levels
Daily number of steps as measured by a sealed pedometer
Time frame: at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
quality-of-life evaluation
Self-efficacy questionnaire SF-36 (Medical Outcomes Study Short-Form 36).
Time frame: at 1 month (end of intervention) and 3 month (follow-up period) compared to baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.